The TEXT and SOFT trials have also confirmed this evidence, showing no difference in the survival outcomes of premenopausal women with estrogen receptor-positive breast cancer treated with GnRHa before or following chemotherapy [73]. This evidence concerns the gene ESR1 and breast carcinoma.